• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用系统性冠状动脉风险评估 2 (SCORE2)和系统性冠状动脉风险评估 2-老年人(SCORE2-OP)算法评估无功能性肾上腺腺瘤患者的心脏代谢风险。

Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms.

机构信息

Department of Nutrition-Related Disease Prevention, Department of Metabolic Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia, Bytom, Poland.

Department of Cardiovascular Disease Prevention, Department of Metabolic Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia, Bytom, Poland.

出版信息

Med Sci Monit. 2024 Nov 27;30:e945899. doi: 10.12659/MSM.945899.

DOI:10.12659/MSM.945899
PMID:39600070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11610524/
Abstract

BACKGROUND Non-functioning adrenal adenomas (NFA) are prevalent tumors often associated with metabolic disturbances compared to the general population. This study aimed to evaluate cardiovascular disease (CVD) risk in 106 patients with NFA using SCORE2 and SCORE2-OP algorithms. MATERIAL AND METHODS The study sample comprised of 106 patients with NFA. CVD risk was assessed using SCORE2 and SCORE2-OP charts. The study population was divided across different categories: low-to-moderate risk, high-risk, very high-risk of CVD. Anthropometric measurements, metabolic indices, lipid profiles, and carbohydrate metabolism parameters were analyzed across different CVD risk groups. RESULTS Very high-risk patients had a higher waist-to-hip ratio (WHR) value (0.95; 0.89-0.98) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.0049). Also, high-risk patients had a higher WHR value (0.92; 0.87-0.97) compared to low-to-moderate risk patients (0.89; 0.84-0.91; P=0.032). Patients with low-to-moderate CVD risk had significantly lower fasting glucose levels compared to patients with high CVD risk (5.35; 5.08-5.61 vs 5.78; 5.39-6.03; P=0.0093) as well as compared to patients with very high risk (5.35; 5.08-5.61 vs 5.83; 5.22-6.28; P=0.0230). There was no significant difference in lipid parameters and atherogenic indices between the groups based on CVD risk according to SCORE2 and SCORE2-OP. CONCLUSIONS Elevated fasting glucose levels are significantly associated with higher CVD risk in NFA patients, particularly in high and very high-risk group. Systolic blood pressure and WHR were identified as cost-effective measures for predicting of CVD among NFA patients. Metabolic indices did not show any significant differences across CVD risk groups.

摘要

背景

与普通人群相比,无功能性肾上腺腺瘤(NFA)是一种常见的代谢紊乱相关肿瘤。本研究旨在使用 SCORE2 和 SCORE2-OP 算法评估 106 例 NFA 患者的心血管疾病(CVD)风险。

材料和方法

研究样本包括 106 例 NFA 患者。使用 SCORE2 和 SCORE2-OP 图表评估 CVD 风险。根据不同的 CVD 风险类别将研究人群分为低至中度风险、高风险和极高风险。对不同 CVD 风险组的人体测量指标、代谢指数、血脂谱和糖代谢参数进行分析。

结果

极高风险患者的腰围-臀围比(WHR)值(0.95;0.89-0.98)高于低至中度风险患者(0.89;0.84-0.91;P=0.0049)。此外,高风险患者的 WHR 值(0.92;0.87-0.97)高于低至中度风险患者(0.89;0.84-0.91;P=0.032)。与高 CVD 风险患者(5.35;5.08-5.61 与 5.78;5.39-6.03;P=0.0093)和极高风险患者(5.35;5.08-5.61 与 5.83;5.22-6.28;P=0.0230)相比,低至中度 CVD 风险患者的空腹血糖水平显著降低。根据 SCORE2 和 SCORE2-OP,各组之间的血脂参数和致动脉粥样硬化指数没有差异。

结论

空腹血糖升高与 NFA 患者的 CVD 风险显著相关,尤其是在高风险和极高风险组。收缩压和 WHR 被确定为预测 NFA 患者 CVD 的具有成本效益的措施。代谢指数在 CVD 风险组之间没有显示出任何显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/34b22a66f76e/medscimonit-30-e945899-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/574c0ac85628/medscimonit-30-e945899-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/d87f1676fcad/medscimonit-30-e945899-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/3b669fb20e47/medscimonit-30-e945899-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/d374d6842788/medscimonit-30-e945899-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/373b39bd7e29/medscimonit-30-e945899-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/0bd26ff6bc50/medscimonit-30-e945899-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/df84e415fc3c/medscimonit-30-e945899-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/cee50d888b9d/medscimonit-30-e945899-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/34b22a66f76e/medscimonit-30-e945899-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/574c0ac85628/medscimonit-30-e945899-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/d87f1676fcad/medscimonit-30-e945899-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/3b669fb20e47/medscimonit-30-e945899-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/d374d6842788/medscimonit-30-e945899-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/373b39bd7e29/medscimonit-30-e945899-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/0bd26ff6bc50/medscimonit-30-e945899-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/df84e415fc3c/medscimonit-30-e945899-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/cee50d888b9d/medscimonit-30-e945899-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/665a/11610524/34b22a66f76e/medscimonit-30-e945899-g009.jpg

相似文献

1
Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms.使用系统性冠状动脉风险评估 2 (SCORE2)和系统性冠状动脉风险评估 2-老年人(SCORE2-OP)算法评估无功能性肾上腺腺瘤患者的心脏代谢风险。
Med Sci Monit. 2024 Nov 27;30:e945899. doi: 10.12659/MSM.945899.
2
Predicting cardiovascular morbidity and mortality with SCORE2 (OP) and Framingham risk estimates in combination with indicators of biological ageing.结合生物学衰老指标,用SCORE2(OP)和弗雷明汉姆风险评估预测心血管疾病的发病率和死亡率。
Age Ageing. 2025 Mar 28;54(4). doi: 10.1093/ageing/afaf075.
3
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort.系统性冠状动脉风险评估 2 (SCORE2)和 SCORE2-老年人在 EPIC-Norfolk 前瞻性人群队列中的验证。
Eur J Prev Cardiol. 2024 Jan 25;31(2):182-189. doi: 10.1093/eurjpc/zwad318.
4
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP.包括衡量慢性肾脏病的措施,以改善 SCORE2 和 SCORE2-OP 的心血管风险预测。
Eur J Prev Cardiol. 2023 Jan 11;30(1):8-16. doi: 10.1093/eurjpc/zwac176.
5
[Cardiovascular risk assessment among patients with hypertension based on SCORE2 and SCORE-OP algorithms in black Africans].基于SCORE2和SCORE-OP算法对非洲裔高血压患者进行心血管风险评估
Ann Cardiol Angeiol (Paris). 2023 Jun;72(3):101602. doi: 10.1016/j.ancard.2023.101602. Epub 2023 May 13.
6
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.SCORE2-OP 风险预测算法:估计四个地理风险地区老年人的新发心血管事件风险。
Eur Heart J. 2021 Jul 1;42(25):2455-2467. doi: 10.1093/eurheartj/ehab312.
7
Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model.亚太地区心血管疾病的风险预测:SCORE2亚太模型
Eur Heart J. 2025 Feb 21;46(8):702-715. doi: 10.1093/eurheartj/ehae609.
8
Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe.验证 SCORE2 风险预测算法在葡萄牙人群中的应用:一种用于估计欧洲人群 10 年心血管疾病发生率的新模型。
Rev Port Cardiol. 2024 Aug;43(8):437-444. doi: 10.1016/j.repc.2023.10.011. Epub 2024 Feb 21.
9
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm.根据 SCORE2-Diabetes 算法,骨蛋白与心血管风险相关。
Cardiovasc Diabetol. 2024 Aug 24;23(1):311. doi: 10.1186/s12933-024-02406-9.
10
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.新的系统性冠状动脉风险评估(SCORE2 和 SCORE2-OP)评估了接受尼罗替尼或帕纳替尼治疗的慢性髓性白血病患者发生动脉闭塞性事件的风险。
Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28.

引用本文的文献

1
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者心血管风险评分、代谢参数及实验室指标的影响
Life (Basel). 2025 Apr 29;15(5):722. doi: 10.3390/life15050722.
2
Estimation of Cardiovascular Risk Using SCORE2, REGICOR and Vascular Age Scales in Spanish Healthcare Workers: A Retrospective Longitudinal Study.使用SCORE2、REGICOR和血管年龄量表评估西班牙医护人员的心血管风险:一项回顾性纵向研究。
Healthcare (Basel). 2025 Feb 10;13(4):375. doi: 10.3390/healthcare13040375.

本文引用的文献

1
Could a nonfunctional adrenal incidentaloma be a risk factor for increased carotid intima-media thickness and 10-year cardiovascular mortality based on the SCORE algorithm? A study from a single centre in Poland.波兰单中心研究:无功能性肾上腺意外瘤是否基于 SCORE 算法成为颈动脉内中膜厚度增加及 10 年心血管死亡率的危险因素?
Endokrynol Pol. 2023;74(6). doi: 10.5603/ep.95139. Epub 2023 Nov 23.
2
Cardiovascular Risk Markers in Adults With Adrenal Incidentaloma and Mild Autonomous Cortisol Secretion.成年人肾上腺意外瘤伴轻度自主皮质醇分泌的心血管风险标志物。
J Clin Endocrinol Metab. 2024 Feb 20;109(3):e1020-e1028. doi: 10.1210/clinem/dgad665.
3
Do Non-Functional Adrenal Adenomas Affect Metabolic Profile and Carotid Intima-Media Thickness? A Single Centre Study from Poland.
无功能肾上腺腺瘤会影响代谢指标和颈动脉内膜中层厚度吗?来自波兰的一项单中心研究。
J Clin Med. 2023 Jul 11;12(14):4612. doi: 10.3390/jcm12144612.
4
Management of Adrenal Cortical Adenomas: Assessment of Bone Status in Patients with (Non-Functioning) Adrenal Incidentalomas.肾上腺皮质腺瘤的管理:对(无功能)肾上腺偶发瘤患者骨状态的评估
J Clin Med. 2023 Jun 24;12(13):4244. doi: 10.3390/jcm12134244.
5
For small (1-3cm) nonfunctional adrenal incidentaloma (NFAI), which option is more appropriate for conservative treatment or surgery?对于直径小于 3cm 的无功能性肾上腺意外瘤(NFAI),哪种治疗方案更适合保守治疗还是手术治疗?
Front Endocrinol (Lausanne). 2023 Feb 1;14:1119251. doi: 10.3389/fendo.2023.1119251. eCollection 2023.
6
Adrenal incidentaloma: Do patients with apparently nonfunctioning mass or autonomous cortisol secretion have similar or different clinical and metabolic features?肾上腺偶发瘤:明显无功能肿块或自主性皮质醇分泌的患者是否具有相似或不同的临床和代谢特征?
Clin Endocrinol (Oxf). 2023 May;98(5):662-669. doi: 10.1111/cen.14861. Epub 2023 Jan 9.
7
Metabolic syndrome and Visceral Adiposity Index in non-functional adrenal adenomas.非功能性肾上腺腺瘤中的代谢综合征和内脏脂肪指数。
Arch Endocrinol Metab. 2023 Mar 30;67(3):323-329. doi: 10.20945/2359-3997000000547. Epub 2022 Dec 1.
8
Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.肾上腺切除术可改善无功能肾上腺意外瘤患者的血压控制,并改善自主皮质醇分泌患者的血糖和血脂控制。
Endocrine. 2022 Oct;78(1):142-150. doi: 10.1007/s12020-022-03120-w. Epub 2022 Jun 25.
9
Cardiometabolic profile and urinary metabolomic alterations in non-functioning adrenal incidentalomas: A review.非功能性肾上腺意外瘤患者的心脏代谢特征和尿液代谢组学改变:综述。
Clin Endocrinol (Oxf). 2022 Dec;97(6):693-701. doi: 10.1111/cen.14745. Epub 2022 Apr 27.
10
Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.非功能性肾上腺偶发瘤随访期间肿瘤生长及自主性皮质醇分泌发展的预测因素
J Clin Med. 2021 Nov 25;10(23):5509. doi: 10.3390/jcm10235509.